Navigation Links
FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults
Date:5/21/2008

SOUTH SAN FRANCISCO, Calif., May 21 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's electronic supplemental New Drug Application (sNDA) filing to expand the indication for Zingo to treat pain associated with peripheral IV insertions and blood draws in adults. Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system is already approved by the FDA to provide local analgesia prior to peripheral IV insertions and blood draws in children three to 18 years of age.

Acceptance for filing of a sNDA means that the FDA has found the company's submission to be sufficiently complete to review. This review is a standard review, and under the Prescription Drug User Fee Act (PDUFA), the agency makes a decision regarding marketing clearance of a product candidate within 10 months of the date of its submission. The sNDA for Zingo was submitted on March 10, 2008.

"As we approach the commercial launch of Zingo in the pediatric population in June, FDA's acceptance of our sNDA filing for adults marks another significant step forward for growing the Zingo franchise," said John P. McLaughlin, chief executive officer of Anesiva. "We believe that Zingo can offer significant relief to adults who experience pain upon peripheral venous access procedures, not only in the United States but also worldwide."

Venous access procedures, like IV insertions and blood draws, are among the most common procedures performed at a hospital. In 2004, more than 245 million adult peripheral venous access procedures and more than 18 million pediatric peripheral venous access procedures were performed in hospitals in the United States.(1) '/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
2. FDA Accepts Sucampos sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
3. FDA Accepts Ranexa(R) sNDA and NDA for Filing
4. EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
5. Imaging Diagnostic Systems Accepts Resignations of Outside Directors
6. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
7. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
8. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
9. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
10. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
11. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 More than 5 ... about 1 in 3 seniors will die with Alzheimer’s ... These jaw-dropping figures have shocked many Americans into looking ... help prevent these tragic age-related cognitive disorders. Jonathan Weisman, ...
(Date:1/15/2014)... 2013 was a banner year of continued innovation ... continued independent research led by the team at Wake ... million grant from the Susanne Marcus Collins Foundation, had ... reviewed journal, Amy Grant highlighted Brainwave Optimization® in First ...
(Date:1/14/2014)... 2014 Date: Friday, April 11, 2014 , ... Club, 1360 Almshouse Road, Warrington, Pa. , Details: ... dedicated to finding a cure for hepatitis B and improving ... its annual Crystal Ball on Friday, April 11 at Warrington ...
(Date:1/14/2014)... 14, 2014 As pet owners drew up their lists of ... wrote: "Take better care of my furry companion." Nowadays there are ... top-brand carrying cases to take the little canine or feline darlings ... compelled to buy some pricey toys at the pet store. But ...
Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... movie about giant robots that undergo structural ... a scientific study about structural transformations within single ... of novel materials that will serve next-generation energy ... at the U.S. Department of Energy (DOE),s Lawrence ...
... 8, 2011 Northwest Biotherapeutics (OTC Bulletin Board: ... equity investment on June 28, 2011, by The Richard ... newly issued common stock of the Company to the ... 31, 2011, by investment funds managed by Whitebox Advisors, ...
... 7, 2011 For the first time since stem ... isolated a human blood stem cell in its purest ... regenerating the entire blood system. This breakthrough opens the ... to treat cancer and other debilitating diseases more effectively. ...
Cached Biology Technology:Nanocrystal transformers 2Nanocrystal transformers 3Nanocrystal transformers 4Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe 2Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe 3Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe 4"Pure" Human Blood Stem-Cell Discovery Opens Door to Expanding Cells for More Clinical Use 2"Pure" Human Blood Stem-Cell Discovery Opens Door to Expanding Cells for More Clinical Use 3
(Date:4/17/2014)... to produce hydrogen sulfide in order to properly multiply ... from the Center for Craniofacial Molecular Biology at the ... Songtao Shi, principal investigator on the project, said the ... the flow of calcium ions. The essential ions activate ... or the creation of new bone tissue, and keeps ...
(Date:4/17/2014)... release is available in German . ... pay the protection money demanded of him, he can expect ... required, however, as fear of the consequences is enough to ... in parasitic birds, which lay their eggs in other birds, ... the brood parasites take their revenge by destroying the entire ...
(Date:4/17/2014)... have hit on a novel method to help ... and most effective treatment possible., Kidney stones represent ... developing world. If left untreated, apart from being ... and other complications. In many patients treated successfully, ... more effective pathological approach to diagnosis and treatment ...
Breaking Biology News(10 mins):Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... 2004, Washington University in St. Lous researcher Jianmin Cui was ... channel his lab had been studying for five years. ... a large family whose members suffered from epilepsy, sudden attacks ... and paroxysmal dyskinesia (GEPD). By analyzing the DNA of ...
... attacks in the United States are fostering development of ... to protect people against the potentially deadly bacteria in ... sweeping overview of scientific research on medical technology to ... Journal of Medicinal Chemistry . In ...
... are reporting that particle size affects the toxicity of zinc ... 100 nanometers are slightly more toxic to colon cells than ... equivalent amounts of soluble zinc, and direct particle to cell ... in ACS, Chemical Research in Toxicology , a monthly ...
Cached Biology News:Solving the puzzle of the BK ion channel 2Solving the puzzle of the BK ion channel 3Solving the puzzle of the BK ion channel 4Solving the puzzle of the BK ion channel 5New medical weapons to protect against anthrax attacks 2
MpV17 transgene, murine homolog, glomerulosclerosis...
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Recombinant Ovine (Sheep) Prolactin, Ultra Pure...
Human LT beta R/TNFRSF3 Phycoerythrin MAb (Clone 71319)...
Biology Products: